Drug intelligence / Profile preview

nigella sativa

Development stage
Phase 3
Lead developer
TriNutra
Administration
Oral, Topical, Sublingual
01

Overview

**Nigella sativa** is a medicinal botanical derived from the seeds of *Nigella sativa* L., commonly used as a dietary supplement and traditional herbal medicine. It is not a single chemically defined active pharmaceutical ingredient: preparations may contain whole or powdered seed, fixed oil, volatile oil, or extracts with variable phytochemical composition. Thymoquinone is a commonly measured volatile-oil constituent and pharmacological marker, but it is not synonymous with the full botanical product. Clinical investigations have evaluated oral preparations for type 2 diabetes, obesity-related metabolic measures, dyslipidemia, prediabetes, and influenza-like illness prevention, as well as a topical 5% gel for prevention of acute radiation dermatitis during breast-cancer radiotherapy. A placebo-controlled one-year study reported improved glycemic and oxidative-stress measures with 2 g/day oral *N. sativa* added to standard oral antidiabetic therapy; however, the heterogeneous, nonstandardized nature of botanical preparations prevents assignment of a single validated molecular mechanism or pharmaceutical indication to the species as a whole. ([journals.plos.org](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0113486))

Brand names
black seedblack cuminhabbatul barakahkalonji
Other names
Nigella sativa L.black seedkalonji
02

Targets

COXALB (Human serum albumin)15-LOX (Lysyl Oxidase)ACE (Angiotensin Converting Enzyme)CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on nigella sativa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nigella sativa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call